This finding is heavily weighted by the Third International Stroke Trial (IST-3), which evaluated the effect of BPR in patients undergoing reperfusion treatment using intravenous tissue plasminogen activator (tPA) [17]. This evidence concerns the gene PLAT and Stroke.